Ventaleon CEO on inhaled drugs for influenza

Ulrich Dauer, CEO of Ventaleon, speaks to Mike Ward, global director of content for Informa Pharma Insights, at the 2017 BIO-Europe partnering conference about the company's pipeline of inhaled treatments against viral infections. Ventaleon's lead product candidate is a first-in-class inhaled version of aspirin (acetylsalicylic acid) that is in Phase II for severe influenza.